Skip to main content

Page last checked

Retatrutide

Retatrutide clinical trials, cost and availability

There is no lawful way to buy retatrutide in the United States. It has no approved product, no brand, no pharmacy price and no prescription anyone can write for it outside a clinical trial. Every site selling it is selling an unapproved drug.

Source: ClinicalTrials.gov and FDA’s letters, read 2026-08-12

What matters first

FDA-approved product
None
Public access route
Registered clinical trials only
Trial program
32 studies; 1 still enrolling
FDA warning letters
16 naming retatrutide

Retatrutide is the only molecule in this section with nothing to compare. The other two have brands, labels, published prices and a savings card. This one has a trial program and a large number of websites.

Why there is no price

There is no cheapest, because there is no price. A price is something a seller publishes for an approved product, and no approved retatrutide product exists.

The figures that circulate are what unapproved sellers charge for a vial of powder. Nobody has established what is in those vials — not the strength, not the purity, not that the contents are the drug on the label.

The only route that exists is a clinical trial, and a trial does not sell anyone anything. The trial pipeline page shows which programs are recruiting and how far along they are.

A site selling it as a research chemical

No lawful route

A website sells a vial of powder labeled for laboratory use, usually with a line saying it is not for human consumption.

Nobody asks you for one, and that is the tell. A seller who does not need a prescription is not selling you a medicine, whatever the vial says.

There is no lawful route here to a person. These are unapproved drugs, and selling one to a consumer in the United States is what most of FDA’s letters to these sites are about.

The only route that exists

A clinical trial, which sells nobody anything. Sponsors register their studies, and the registry is public.

32 registered studies; the program has reached phase 3, and one is still enrolling.

Registered studiesStill enrollingHighest phase reached
321PHASE3

We read this from ClinicalTrials.gov on 2026-08-23. Every study, with its phase and the completion date its sponsor states, sits on the pipeline page.

A registered trial is not a supply route and this page is not a referral to one. Whether a study is right for anybody is a question for a clinician, not for a website.

Registered site status

Find sites sponsors marked as recruiting

Search the location rows sponsors filed. We show a site as recruiting only when every source row for that exact study and place agrees.

CompoundRetatrutide

Retatrutide site records

read 2026-08-17

  • 473 recruiting
  • 91 other statuses
  • 0 conflicts withheld
Reading the saved site records…

These sources are submitted by study sponsors. “Recruiting” does not prove a slot is open, and it does not mean you are eligible. The study team decides that. HealthspanLedger stores no contact details; the official record is the current source.

The two routes that apply

The other five do not. There is no brand to insure, no manufacturer selling direct, no Medicare program and no lawful compounded version, because all of those need an approved product to exist first.

  1. A prescription from a clinician you see

    Open

    The ordinary route. A doctor, nurse practitioner or physician assistant assesses you and writes a prescription, and a pharmacy fills it.

    Prescription
    Yes, and it is not optional. Federal law makes every drug on this site prescription-only, which means it cannot lawfully be sold to you without one.
    What is published about cost
    Whatever your plan charges, plus the manufacturer’s savings card if your plan covers the drug. The cards take most people to about $25 a month.
    Who it does not work for
    Nobody, in principle. In practice the delay is getting an appointment, and plans differ wildly on whether they cover a GLP-1 for weight at all.

  2. A site selling it as a research chemical

    No lawful route

    A website sells a vial of powder labeled for laboratory use, usually with a line saying it is not for human consumption.

    Prescription
    Nobody asks you for one, and that is the tell. A seller who does not need a prescription is not selling you a medicine, whatever the vial says.
    What is published about cost
    Cheap, and the price is the product. Nothing about what is in the vial is established by anyone: not the strength, not the purity, not that it is the drug on the label.
    Who it does not work for
    There is no lawful route here to a person. These are unapproved drugs, and selling one to a consumer in the United States is what most of FDA’s letters to these sites are about.
    In FDA’s letters
    A large block of the published research is exactly this: sites offering unapproved drugs to United States consumers over the internet. Several letters name a web address rather than a company.

FDA has written letters about a drug nobody sells lawfully

FDA has published 16 warning letters that mention retatrutide somewhere in the text, read on 12 August 2026. 16 of them were issued in the last 24 months and are named on this site.

Retatrutide turns up in FDA’s published warning letters even though no approved product exists, which tells you what the letters are about. They name internet sellers and telehealth services, not a manufacturer.

That is the whole record for this molecule: no label, no price, no pharmacy, and an enforcement trail.

Company, as FDA names itLetter issue dateSubject, in FDA’s wordsClose-outFDA’s page
Gram PeptidesUnapproved New Drugs Sold Over the InternetNone publishedRead the letter
Lovega LLC dba Pink Pony PeptidesUnapproved New Drugs Sold Over the InternetNone publishedRead the letter
Mile High Compounds LLCUnapproved New Drugs Sold Over the InternetNone publishedRead the letter
Prime SciencesUnapproved New Drugs Sold Over the InternetNone publishedRead the letter
GenoGenix LLCCompounding Pharmacy/Adulterated Drug ProductsNone publishedRead the letter
Darmerica, LLCCGMP/Active Pharmaceutical Ingredient (API)/Adulterated/MisbrandedNone publishedRead the letter
Amazing MedsUnlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)None publishedRead the letter
ASN-LABSUnlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)None publishedRead the letter
EA WORKS Limited Liability Company dba Trust LabsUnlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)None publishedRead the letter
GenLabMedsUnlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)None publishedRead the letter
GLP-1 SolutionUnlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)None publishedRead the letter
MedClub by Dr. JennUnlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)None publishedRead the letter
Prime Vitality, Inc. dba Prime PeptidesUnapproved New Drugs/MisbrandedNone publishedRead the letter
Summit Research PeptidesUnapproved New Drugs/MisbrandedNone publishedRead the letter
SwisschemsUnapproved New Drugs/MisbrandedNone publishedRead the letter
Xcel Research LLCUnapproved New Drugs/MisbrandedNone publishedRead the letter

A warning letter is FDA telling a company what the agency believes it found. It is not a court ruling and not proof that anyone was harmed.

A seller missing from this list is a seller FDA has published no letter about. That is all it means. Many sites selling these drugs are not registered with FDA at all, so nothing they do produces a letter in the first place.

Read from FDA’s published warning letters on 12 August 2026.

Questions people actually ask

Why do so many sites sell retatrutide if it is not approved?

Because an unapproved drug has no manufacturer controlling who sells it. Somebody makes the powder, sells it as a research chemical, and leans on the label that says so.

FDA’s position on this is not ambiguous. Selling an unapproved drug to people in the United States is the subject of a large block of its published letters.

Is retatrutide going to be approved?

It is in trials. That is a real answer and it is the only one available, because an approval is a decision nobody has made yet and no page can predict.

The pipeline page lists every registered program, its phase and the completion date its sponsor states, read from ClinicalTrials.gov.

2Scope and reviewWhat this molecule record cannot cover, and how it is checked

What we cannot answer yet

  • This is a description of routes that exist and prices that are published. It is not advice about which one to take, and it is not medical or legal advice.
  • Only a licensed clinician can write a prescription. Nothing here helps anyone get a prescription.
  • Prices move. Every figure on the cost pages carries the date its source was read, and manufacturer terms change without notice.
  • Insurance is not covered in any depth, because plans differ so much that a general statement about coverage would be wrong for most readers.
  • State law is not covered. Pharmacy practice and telehealth rules are set state by state and they differ.

How we check the information

Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewer

Reviewed 2026-08-12

We do not name or rank sellers. Retatrutide has no approved prescribing schedule. The published numbers come from clinical trials, not instructions for personal use. Read the sourcing methodology, and corrections go to contact@healthspanledger.com.

Sources

  1. 21 U.S.C. § 353(b) — the provision that makes these drugs prescription-only · United States Code, 2023 Edition — via GovInfo · retrieved 2026-08-12
  2. FDA warning letters — the published enforcement record, searchable by company and by text · U.S. Food and Drug Administration · retrieved 2026-08-12
  3. BeSafeRx — FDA’s guidance on buying medicine from a website · U.S. Food and Drug Administration · retrieved 2026-08-12
  4. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of 06/15/2026) · U.S. Food and Drug Administration · retrieved 2026-08-12
  5. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (content current as of 04/01/2026) · U.S. Food and Drug Administration · retrieved 2026-08-12
  6. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (news release, April 30, 2026) · U.S. Food and Drug Administration · retrieved 2026-08-12

The pages behind this one

The local questions nobody publishes

What a counter has in the drawer today is the part nobody publishes at all.

The peptide personal-import checklist

6 personal-import conditions are published as a checklist rather than a blanket permission.

What “research use only” changes in Canada

A “research use only” label does not legalize an unauthorized peptide drug.

Who each advertised price is actually for

Every one of the 8 cards excludes Medicare and Medicaid, in the manufacturer’s own words.

The tirzepatide letters, and what they allege

Tirzepatide is sold in the United States as Zepbound and Mounjaro, both from Eli Lilly, and both need a prescription.

Getting semaglutide: what exists and what it costs

7 routes apply to semaglutide, walked in the order a reader meets them.